|
|
Volumn 332, Issue 7543, 2006, Pages 683-
|
|
Severe adverse reactions prompt call for trial design changes.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CD28 ANTIGEN;
LYMPHOCYTE ANTIGEN RECEPTOR;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY TGN1412;
ARTICLE;
DRUG POTENTIATION;
HUMAN;
HUMAN EXPERIMENT;
IMMUNOLOGY;
MALE;
METHODOLOGY;
MULTIPLE ORGAN FAILURE;
PHASE 1 CLINICAL TRIAL;
STANDARD;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD28;
CLINICAL TRIALS, PHASE I;
HUMAN EXPERIMENTATION;
HUMANS;
MALE;
MULTIPLE ORGAN FAILURE;
RECEPTORS, ANTIGEN, T-CELL;
RESEARCH DESIGN;
|
|
EID: 33645519119
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.332.7543.683 Document Type: Article |
|
Times cited : (19)
|
|
References (0)
|
